Drug Profile
KF 31334
Latest Information Update: 24 Apr 2007
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Class Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Asthma in Japan (Inhalation)
- 31 Oct 2002 Preclinical trials in Asthma in Japan (Inhalation)